STARD3NL

STARD3NL (MENTHO) is a late endosomal membrane protein that organizes cholesterol-containing subdomains of the endosomal limiting membrane and contributes to inter-organelle cholesterol transport (PMID:12393907, PMID:16709157). It is anchored by a four-transmembrane MENTAL domain that both targets the protein to late endosomes and binds cholesterol in vivo; through this domain STARD3NL self-associates and forms hetero-interactions with the related protein MLN64/STARD3 within late endosomal membranes (PMID:15718238, PMID:16709157). STARD3NL further bridges late endosomes to the endoplasmic reticulum by binding directly to the ER-anchored VAP proteins VAP-A and VAP-B, establishing ER–late endosome membrane contact sites that influence endosome dynamics (PMID:27068960). Independent of its endosomal role, STARD3NL acts in bone biology as a negative regulator of osteogenesis: it binds Annexin A2 (ANXA2) and suppresses β-catenin, thereby inactivating Wnt/β-catenin signaling and inhibiting osteogenic differentiation, with loss of STARD3NL activating Wnt signaling and reversing bone loss in vivo (PMID:35098646). STARD3NL protein levels are controlled by the E3 ubiquitin ligase FBXO6, which interacts with STARD3NL and promotes its ubiquitin-mediated degradation, placing STARD3NL downstream of FBXO6 in the control of osteoblast differentiation (PMID:41483826).

1. 2002 Medium

   Established STARD3NL as a bona fide late endosomal membrane protein with an intrinsic role in endocytic transport rather than a passive membrane anchor.

   Evidence cDNA cloning, subcellular fractionation/localization, and overexpression with a morphological (enlarged endosome) readout

   PMID:12393907

   Open questions at the time

   • Molecular mechanism by which overexpression enlarges endosomes not defined
   • Functional consequence of the two phosphorylated isoforms unknown
2. 2005 High

   Defined the MENTAL domain as the functional unit, showing it binds cholesterol in vivo and mediates STARD3NL homo-interaction and hetero-interaction with MLN64/STARD3 in endosomal membranes.

   Evidence In vivo photocholesterol binding, GST pull-down, co-immunoprecipitation, and live-cell FRET with fluorescent fusion proteins

   PMID:15718238

   Open questions at the time

   • Stoichiometry and structural basis of cholesterol binding not resolved
   • Functional output of the STARD3NL–MLN64 hetero-complex not established
3. 2006 Medium

   Consolidated the MENTAL domain model in which STARD3NL and MLN64 define discrete cholesterol-rich endosomal subdomains potentially functioning in cholesterol transport.

   Evidence Review synthesizing prior cholesterol-binding, Co-IP, and localization data from the same group

   PMID:16709157

   Open questions at the time

   • Direct demonstration of cholesterol transport activity absent
   • No reconstitution of the proposed transport function
4. 2016 Medium

   Positioned STARD3NL as a tether linking late endosomes to the ER via direct binding to VAP-A and VAP-B, forming membrane contact sites that govern endosome dynamics.

   Evidence Protein interaction and membrane contact site characterization (review citing primary data)

   PMID:27068960

   Open questions at the time

   • FFAT-like motif mediating VAP binding not mapped in the timeline
   • Quantitative contribution of these contacts to cholesterol flux unmeasured
5. 2022 Medium

   Revealed a distinct signaling role in bone, where STARD3NL binds Annexin A2 to suppress β-catenin and inhibit Wnt-driven osteogenesis, with in vivo relevance to osteoporosis.

   Evidence Co-IP, siRNA/shRNA knockdown, β-catenin nuclear translocation and Wnt reporter assays, and AAV9 silencing in an OVX osteoporotic mouse model

   PMID:35098646

   Open questions at the time

   • Mechanistic link between ANXA2 binding and β-catenin suppression unresolved
   • Whether this signaling role depends on STARD3NL's endosomal/cholesterol functions unknown
6. 2026 Medium

   Identified upstream control of STARD3NL abundance, showing FBXO6 targets it for ubiquitin-mediated degradation in a pathway regulating osteoblast differentiation.

   Evidence Label-free proteomics, FBXO6–STARD3NL Co-IP, knockdown, osteogenic differentiation assays, and epistasis rescue

   PMID:41483826

   Open questions at the time

   • Ubiquitination site(s) on STARD3NL not mapped
   • Whether FBXO6 regulates the endosomal/cholesterol functions of STARD3NL untested

• How STARD3NL's endosomal cholesterol-transport function mechanistically relates to its Wnt/osteogenic signaling role, and whether the two are coupled, remains unresolved.
• No unified model linking cholesterol/MCS function to Wnt regulation
• Direct cholesterol-transport activity not biochemically demonstrated
• Structural data on the MENTAL domain and its ligand/partner interfaces absent